From antibiotics to analgesics, explosives to pesticides, electrochemically activated molecules are a very large class of application-based molecules, so large: that they can be any type of molecule so long as they're electrochemically activated, and that's where the enzymology comes in.

​​

Because of the mechanistic sourcing of bioactivation in electrochemical activation: devices like the CGP are able to be customized specifically to produce desired outcomes and results. The pseudo-substrate specific activation results of the CGP are able to be achieved by controlling: filtration size limits, applied operational voltages and currents, and residency time, these are the basic parameters for the construction of the artificial organs by Innovative Potential.

​

All artificial enzymes are CGPs (patent protected) or some derivative of the initial EAC​ apparatus, figure 1 provides an overview of the technology readiness level (TRL) of EAC as a coherent and functioning technology independently of any CGP embodiments.

​

​​

​

​

​

​

​

​

​

​

​

​

​

​

Figure 1. Electrochemically Activated Chemotherapy (EAC) technology readiness level (TRL)​. The overall EAC​ TRL is 7-of-9; and the areas of importance are Regulation (5-of-9); Engineering (6-of-9); Medicine (7-of-9); Science (9-of-9); and Business (6-of-9).

​

The EAC TRL are determined by accounting for the large publicly available molecular, medical, and scientific information databases, and please understand that a majority of the EAC work done is pre-clinical, that is to say before you have an EAC application.

​

The thesis's EAC apparatus acts ​as an EAC demonstration unit to other pharmaceutical companies, research institutes, universities, colleges, and even high schools.

​​​​

​